Abstract:Abstract Background Preeclampsia is a severe complication of pregnancy that can impose a significant economic burden and pose a serious threat to the health of both mothers and infants. Currently, there are no effective treatment methods for established preeclampsia other than delivering the placenta. Methods We performed differential analysis and weighted correlation network analysis (WGCNA) on RNA-seq datasets to identify highly associated blood system biomarkers in preeclampsia. The expression levels and potential predictive value of these biomarkers were validated through ELISA experiments. Subsequently, multiple bioinformatics analyses were conducted to predict the biological activities and gene mappings of the selected genes. The changes in the proportions of blood immune cells and abnormal cell-cell communication in the pathogenesis of preeclampsia were explored through analysis of single-cell transcriptomics data from blood samples. Potential candidate drugs were predicted using the DrugBank database. Results We identified and preliminarily validated the expression levels of F2R Like Trypsin Receptor 1 (F2RL1) and Granzyme H (GZMH) in maternal blood samples from preeclampsia through quantitative experiments. Gene Set Enrichment Analysis (GSEA) indicated that F2RL1 is involved in the regulation of classical signaling pathways, including Toll-like receptor signaling pathway, pattern recognition receptor signaling pathway, oxidative stress-induced intrinsic apoptotic signaling pathway, and vesicle targeting processes. GZMH is primarily involved in immune processes associated with natural killer cells and also regulates lymphocyte chemotaxis. Analysis of single-cell sequencing datasets revealed significant changes in T cells and hematopoietic Stem Cell Growth Factor (HSC G-CSF) in the maternal blood system during the pathogenesis of preeclampsia. Receptor-ligand analysis and protein-drug analysis highlighted the important role of aspirin in the treatment of preeclampsia, as well as the potential value of tyrosine kinase inhibitors in preeclampsia treatment. Conclusion: This study identified the preeclampsia biomarkers F2RL1 and GZMH, which showed good diagnostic value, and predicted their potential biological functions. The disrupted immune environment in the maternal blood system and potential therapeutic drugs were explored through single-cell transcriptomics data analysis. This research provides new insights for the prediction of preeclampsia and deepens our understanding of the changes in the maternal blood system's immune environment during preeclampsia. However, further laboratory work and multicenter clinical evidence are still needed to clarify the clinical prospects of these findings.

Partial Least Squares-Based Gene Expression Analysis in Preeclampsia.

Bioinformatics-based Identification of Mirna-, Lncrna-, and Mrna-Associated Cerna Networks and Potential Biomarkers for Preeclampsia.

Integrated analysis of multiple microarray studies to identify novel gene signatures in preeclampsia

Comprehensive Analysis of Differently Expressed and Methylated Genes in Preeclampsia

Identifying Key Genes and Drug Screening for Preeclampsia Based on Gene Expression Profiles

Identification and validation of an angiogenesis-related signature associated with preeclampsia by bioinformatic analysis

Bioinformatics Methods in Biomarkers of Preeclampsia and Associated Potential Drug Applications

Association of a Reduction of G-protein Coupled Receptor 30 Expression and the Pathogenesis of Preeclampsia

Machine Learning and Bioinformatics Framework Integration Reveal Potential Characteristic Genes Related to Immune Cell Infiltration in Preeclampsia.

Prediction of Differentially Expressed Genes and a Diagnostic Signature of Preeclampsia Via Integrated Bioinformatics Analysis

Identification Of Key Genes In Preeclampsia-Associated Trophoblast Cells Using Bioinformatics Analysis

Integration of Single-Cell Sequencing and Transcriptomic Analysis to Identify Novel Diagnostic Biomarkers for Preeclampsia and Explore Changes in Immune Cell Interactions

Integrated analysis of microRNA and mRNA expression profiles in Preeclampsia

Microarray Analysis of Differentially Expressed Genes in Preeclamptic and Normal Placental Tissues.

Exploration of the molecular characteristics and potential clinical significance of shared immune-related genes between preterm preeclampsia and term preeclampsia

Proteomic Analysis Reveals Differential Protein Expression in Placental Tissues of Early-Onset Preeclampsia Patients

Protein Profiling Of Preeclampsia Placental Tissues

Proteome- and Transcriptome-Wide Genetic Analysis Identifies Biological Pathways and Candidate Drug Targets for Preeclampsia

Single-Cell RNA Sequencing and Microarray Analysis Reveal the Role of Lipid-Metabolism-Related Genes and Cellular Immune Infiltration in Pre-Eclampsia and Identify Novel Biomarkers for Pre-Eclampsia

Transcriptomic profiling in hypoxia-induced trophoblast cells for preeclampsia

Unveiling immune tolerance pathways in preeclampsia placenta: implications for molecular targets and discovery of potential biomarkers